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Forced degradationAbstract Two simple, selective and precise stability-indicating reversed-phase liquid chromato-
graphic methods were developed and validated for the determination of mometasone furoate in
two binary mixtures, with formoterol fumarate (Mixture 1) and salicylic acid (Mixture 2). Also,
a forced degradation study of mometasone furoate was carried out including acid and alkali
hydrolysis, oxidation, thermal and photo-degradation. For mixture 1, the method was based on iso-
cratic elution using a mobile phase consisting of (Acetonitrile: 3 mM Sodium lauryl sulfate) (60:40,
v/v) at a ﬂow rate of 1 ml min1. Quantitation was achieved applying dual wavelength detection
where mometasone furoate and its degradation products were detected at 247 nm and formoterol
fumarate and its degradation product were detected at 214 nm at 30 C. For mixture 2 and for
the forced degradation study, separation was based on isocratic elution of mometasone furoate,
its degradation products and salicylic acid on a reversed phase C8 column using a mobile phase
consisting of acetonitrile:water:methanol:glacial acetic acid (60:30:10:0.1, v/v) at a ﬂow rate of
2 mL min1. Quantitation was achieved with UV detection at 240 nm. In addition, products from
alkaline forced degradation of mometasone furoate were veriﬁed by LC–MS. Linearity, accuracy
and precision were found to be acceptable over the concentration range of 10–800 lg mL1 and
5–60 lg mL1 for mometasone furoate and formoterol fumarate, respectively and over the concen-
tration range of 5–320 lg mL1 and 20–1280 lg mL1 for mometasone furoate and salicylic acid,
Figure 1 Chemical s
494 R.I. El-Bagary et al.respectively. The two proposed methods could be successfully applied for the routine analysis of the
studied drugs in their pharmaceutical preparations without any preliminary separation step.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mometasone furoate (MF), 9a,21-dichloro-11b,17-dihydroxy-
16a- methylpregna-1,4-diene-3,20-dione 17-(2-furoate),
(Fig. 1a), is a topical corticosteroid. It has anti-inﬂ
ammatory, anti-pruritic, and vasoconstrictive properties. It is
indicated for a number of conditions such as allergic reactions,
eczema and psoriasis. Corticosteroids act by the induction of
phospholipase A2 inhibitory proteins, collectively called
lipocortins. It is postulated that these proteins control the
biosynthesis of potent mediators of inﬂammation such as
prostaglandins and leukotrienes by inhibiting the release of
their common precursor arachidonic acid (Shaikh et al., 2009).
Formoterol, ((RR)-(±)-N-[2-hydroxy-5-[1-hydroxy-2-[[2-
(4- methoxyphenyl)-1 methylethyl]amino]ethyl]phenyl]forma
mide), (Fig. 1b) is an adrenergic agent with high selectivity
for the b2 receptor (b2-agonist) and has proven to be a very
effective bronchodilating agent (Sardela et al., 2012). Hence,
it is frequently applied therapeutically by means of metered
dose inhalers for the treatment of asthma, bronchospasm
and prophylaxis of exercise-induced bronchospasm.
Salicylic acid (SA), 2-hydroxybenzoic acid, (Fig. 1c) is
widely used as a peeling or keratolytic agent to treat callus,
keratosis or warts. Salicylic acid is further applied in the treat-
ment of acne, psoriasis and photo ageing in various concentra-
tions depending on the desired amount of keratolysis (Bashir
et al., 2005). Salicylic compounds have also been synthesized
for analgesics (acetylsalicylic acid or aspirin) and antipyretics.
Literature survey revealed the determination of mometa-
sone furoate (MF) in plasma by LC-tandem mass spectrome-
try (Sahasranaman et al., 2005), and by HPLC with stability
studies (Teng et al., 2001). Also, MF was determined in its
dosage form by HPLC (Ourique et al., 2012). Kinetic study
of MF in aqueous system (Teng et al., 2003) and supercritical
ﬂuid chromatographic impurity analysis (Wang et al., 2011)tructure of (a) mometasone furowere also carried out. Moreover, determination of MF with
fucidic acid, tazarotene using HPLC (Shaikh et al., 2009;
Ankam et al., 2009) and with nadiﬂoxacin using HPTLC
(Kulkarni et al., 2010) was reported.
Besides, Several methods have been reported for the deter-
mination of formoterol fumarate (FF) by HPLC in mixtures
(Assi et al., 2006; Sule et al., 2012; TRIVEDI et al., 2012;
malik et al., 2011), by Chiral analysis (Samuel et al., 2009),
and with its related substances (Samuel and Muhammad,
2003; Hassib et al., 2011). Several qualitative mass spectrome-
try based methods for the detection of formoterol in the ﬁeld
of doping analysis have been also described (Kang et al.,
2007; Mazzarino and Botre, 2006; Thevis et al., 2003;
Ventura et al., 2000; Peters et al., 2010; Kolmonen et al.,
2009). For its quantitation, several non-mass spectrometric
methods have been described in the frame of pharmacokinetic
experiments (Nadarassan et al., 2007; Butter et al., 1996;
Rosenborg et al., 1999). Quantitative detection methods apply-
ing mass spectrometric detection are limited to a GC–MS
method (Kamimura et al., 1982), a UPLC-MS (Sardela
et al., 2012), and two LC–MS/MS methods (Deventer et al.,
2012; Marzo et al., 2000).
Also, several analytical methods have been reported for the
determination of salicylic acid (SA) in mixtures using spec-
trophotometry (Salinas et al., 1990), colorimetry (Saha and
Baksi, 1985), liquid chromatography (Aguiar et al., 2009;
Akay et al., 2008), ﬂow-through UV spectrophotometric
sensor (Ruiz-Medina et al., 2001) and titrimetric method
(Ruiz-Medina et al., 2001).
Mometasone furoate is incorporated in many pharmaceuti-
cal preparations, as inhaled corticosteroids for the treatment of
bronchial asthma and as anti-inﬂammatory corticosteroids for
the treatment of many skin disorders. The two pharmaceutical
preparations analysed in this manuscript represent these
binary usages of mometasone furoate.ate, (b) formoterol fumarate and (c) salicylic acid.
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reported in any pharmacopoeia. So far, no RP-HPLC
stability-indicating method has been reported for the rapid
simultaneous determination of MF with any of them.
Besides, only degradation kinetics in different pH solutions
(Teng et al., 2003) and thermostability studies in plasma
(Teng et al., 2001) were found in the literature but no full
forced degradation study of mometasone furoate was pub-
lished. Thus, the aim of the present work was to develop sim-
ple, sensitive and selective LC methods for the simultaneous
determination of mometasone furoate and formoterol fuma-
rate (Mixture 1), and for the determination of mometasone
furoate and salicylic acid (Mixture 2). Selectivity was demon-
strated by enhancing alkaline and acidic degradation of
mometasone furoate and formoterol fumarate in mixture 1
and by alkaline degradation of mometasone furoate in mixture
2. Mometasone furoate was found to be stable in acidic
conditions while formoterol fumarate was stable in alkaline
conditions. The two methods were successfully applied to
laboratory prepared mixtures and their pharmaceutical
preparations. Moreover, the present manuscript describes the
degradation behaviour of mometasone furoate under acidic, basic,
oxidative, thermal and photolytic conditions. The method val-
idation is generally performed as per the guidelines published
by the International Conference on Harmonization (ICH).
2. Experimental
2.1. Instrumentation
A chromatographic system consists of Agilent 1200 series (CA,
USA): interface equipped with an Agilent quaternary pump
G1311A, Agilent UV–visible detector G1314B, an Agilent
manual injector G1328B equipped with (20 lL) injector loop,
and an Agilent degasser G1322A.
Separation and quantitation were made on C18 column
(250 · 4.6 mm, 5 lm) –XTerra for mixture 1 and C8 column
(250 mm · 4.6 mm, 7 lm) – Phenomenex for mixture 2 and
for forced degradation study.
2.2. Reagents and reference samples
Mometasone furoate was kindly supplied by Sigma–Aldrich
and was certiﬁed to contain 99.6%. Formoterol fumarate
was supplied by Novartis and was certiﬁed to contain
99.76% and salicylic acid was supplied by Pharco
Pharmaceutical and was certiﬁed to contain 99.7%. HPLC
grade acetonitrile and methanol were supplied by Scharlau,
Spain. Sodium lauryl sulfate was supplied by Parchem.
Bi-distilled water was produced in-house (Aquatron Water
Still, A4000D, UK). Membrane ﬁlters of 0.45 lm were
purchased from Teknokroma (Barcelona, Spain). All the
chemicals were of analytical grade.
Dulera inhaler labelled to contain 200 lg/5 lg of
Mometasone furoate and Formoterol fumarate, respectively,
per actuation (Batch No. H015615), was supplied by
MERCK & CO. Elicasal ointment, nominally containing
0.1%w/w mometasone furoate and 5%w/w Salicylic acid
(Batch No. M0062), was supplied by Jamjoom
Pharmaceuticals Company, KSA.2.3. Chromatographic conditions
2.3.1. Mixture 1
Chromatographic separation was achieved on a C18 column
(250 · 4.6 mm, 5 lm) –XTerra using the mobile phase con-
sisting of acetonitrile: 3 mM sodium lauryl sulfate) (60:40,
v/v) at a ﬂow rate of 1 ml min1. The column temperature
was adjusted at 30 C. UV detector was operated at 247 nm
for MF and its alkaline degradation products and at 214 nm
for FF and its acidic degradation product.
2.3.2. Mixture 2 and forced degradation study
Chromatographic separation was achieved on a C8 column
(250 mm · 4.6 mm, 7 lm) Phenomenex applying isocratic
elution based on a mobile phase consisting of acetonitrile:wa
ter:methanol:glacial acetic acid (60:30:10:0.1, v/v). The mobile
phase was pumped through the column at a ﬂow rate of
2 mL min1. Analyses were performed at ambient temperature
and detection was carried out at 240 nm. The injection volume
was 20 lL.
2.4. Solutions
2.4.1. Stock standard solutions
2.4.1.1. Mixture 1. Stock standard solutions of MF
(2 mg mL1) and FF (0.5 mg mL1) were prepared in
methanol. Appropriate dilutions of theses stock solutions were
prepared using the same solvent used for linearity studies and
assay purposes.
2.4.1.2. Mixture 2. Stock standard solutions of MF
(0.5 mg mL1) and SA (2 mg mL1) were prepared in acetoni-
trile. Appropriate dilutions of theses stock solutions were pre-
pared using the same solvent used for linearity studies and
assay purposes.
2.4.2. Laboratory-prepared mixtures
2.4.2.1. Mixture 1. Solutions containing different ratios of MF
(200–680 lg mL1) and FF (5–17 lg mL1) were prepared by
transferring aliquots from their stock solutions into a series
of 10-mL volumetric ﬂasks and the volume of each was com-
pleted to the mark with methanol.
2.4.2.2. Mixture 2. Solutions containing different ratios of MF
(6–24 lg mL1) and SA (300–1200 lg mL1) were prepared by
transferring aliquots from their stock solutions into a series of
10-mL volumetric ﬂasks and the volume of each was com-
pleted to the mark with acetonitrile.
2.4.3. Sample preparation
2.4.3.1. Mixture 1. The pressurized canister was removed from
the actuator and placed in a plastic bag in upright position and
chilled to 20 C for 30 min then carefully a small hole was
pierced on the shoulder of the canister, allowing the propel-
lants to evaporate and the top was removed. The top and valve
of the opened canister were washed with methanol. 5 mL of
diluent was added in the canister and sonicated to dissolve at
ambient temperature. The content of canister was transferred
to 25 mL volumetric ﬂask. The above procedure was repeated
2 times with 5 mL methanol and the solution was sonicated
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mark with methanol and mixed.
2.4.3.2. Mixture 2. Two grams of Elicasal ointment (for mix-
ture 2) was transferred to a conical ﬂask, taking care to avoid
sticking ointment to the walls of the ﬂask. Twenty-ﬁve mL of
acetonitrile was added and the mixture was heated in a water
bath at 80 C until the ointment melted completely; in
between, the ﬂask was occasionally swirled. The conical ﬂask
content was quantitatively transferred to a 50 mL volumetric
ﬂask. The ﬂask was washed with 2 · 10 mL acetonitrile.
Volume was made up to the mark with acetonitrile and mixed.
Solution was gently cooled then supernatant solution was ﬁl-
tered through a 0.45-lm membrane ﬁlter.
2.5. Procedures
2.5.1. Construction of the calibration curves
For mixture 1, aliquots equivalent to 10–800 lg mL1 of MF
and 5–60 lg mL1 of FF were accurately transferred into
two series of 10-mL volumetric ﬂasks and the volumes were
completed to the mark with methanol.
For mixture 2, aliquots equivalent to 5–320 lg mL1 of MF
and 20–1280 lg mL1 of SA were accurately transferred into
two series of 10 mL volumetric ﬂasks and the volumes were
completed to the mark with acetonitrile.
A volume of 20 lL of each solution was injected in tripli-
cate into the chromatograph under the speciﬁed chromato-
graphic conditions described in Section 2.3.1. for mixture 1
and 2.3.2. for mixture 2. A calibration curve for each com-
pound was obtained by plotting area under the peak (AUP)
against concentration (C).
2.5.2. Assay of laboratory-prepared mixtures
The solutions prepared in Section 2.4.2.1. (For mixture 1) and
in Section 2.4.2.2. (For mixture 2) were injected in triplicate
into the chromatograph under the speciﬁed chromatographic
conditions described in section 2.3.1. and 2.3.2., respectively.
The concentration of each drug was calculated using the spec-
iﬁed regression equation.
2.5.3. Assay of Dulera inhaler
The sample solution, prepared in Section 2.4.3.1., was serially
diluted to get concentrations equivalent to 240–480 lg mL1
and 6–12 lg mL1 of MF and FF, respectively. Samples then
were injected in triplicate and concentrations of MF and FF
were calculated using calibration equations.
2.5.4. Assay of Elicasal ointment
The sample solution, prepared in Section 2.4.3.2., was serially
diluted to get concentrations equivalent to 10–20 lg mL1 and
500–1000 lg mL1 of MF and SA, respectively. Samples then
were injected in triplicate and concentrations of MF and SA
were calculated using calibration equations.
2.6. Forced degradation of mometasone furoate
Forced degradation studies of bulk drug included appropriate
solid state and solution state stress conditions in accordancewith the ICH regulatory guidance (Q1A (R2), 2003; Elkady
and Fouad, 2011). The stock solution was used for the forced
degradation study to provide an indication of the stability indi-
cating property and speciﬁcity of proposed method.
2.6.1. Acid- and base-induced degradation
To 5 mL of MF methanolic stock solution, an appropriate
volume of 2 M HCl was added and the mixture was diluted
with water to 10 mL to reach molarity of 0.1 M, 0.5 M and
1 M HCl, separately. The mixtures were kept at room tem-
perature for 8 h. Alkaline degradation studies were carried
out in a similar manner with molarities of 0.1 M, 0.5 M
and 1 M NaOH for 8 h. These experiments were repeated
at higher temperature of 75 C for 0.5 h while keeping all
other conditions constant. For study in neutral condition,
drug was held in methanol at room temperature for 24 h.
The forced degradation in acidic and basic media was per-
formed in the dark in order to exclude the possible
degradative effect of light. Prior to injection, samples were
withdrawn at appropriate time and were neutralized (in case
of acid and alkali hydrolysis) and the solutions were diluted
with methanol. The total chromatographic run time was
about two times the retention of the drug peak.
2.6.2. Hydrogen peroxide-induced degradation
To 1 mL of MF methanolic stock solution, 5 mL of 6% (v/v)
H2O2 and 30% (v/v) H2O2 were separately added to reach ﬁnal
concentrations of 3% and 15% (v/v) H2O2, respectively. The
prepared mixtures were kept at room temperature for 12 and
5 h, respectively. Also, oxidative degradation reactions were
performed with the aid of heating at 80 C for 1 h.
2.6.3. Thermal and photolytic degradation
The dry powder of the drug was placed in oven at 55 C for
72 h to study dry heat degradation. Powder was dissolved
and diluted with methanol to get ﬁnal concentrations of
(125 lg ml1). The photochemical stability of the drug was
also studied by exposing the drug solution (125 lg ml1) to
sunlight for 72 h.
Twenty microlitres of the resultant solutions were injected
onto column and the chromatograms were run as described
in Section 2.3.2.
2.7. Preparation of mometasone furoate alkaline degradation
products
Mometasone furoate methanolic solution with a concentration
of 50 lg mL1 was incubated in 0.5 N NaOH at room temper-
ature for 1 h. Solution was neutralized before incorporation in
the analysis. This procedure resulted in four degradation
products.
2.8. Preparation of desformyl derivative of formoterol fumarate
Formoterol fumarate (5 mg) was heated at 80 C for 1 hour in
0.5 M hydrochloric acid (10 ml). The solution was cooled and
diluted to 50 ml with water to produce a solution of desformyl
derivative (equivalent to 0.1 mg mL1 FF) in 0.1 M hydrochlo-
ric acid (Hassib et al., 2011).
Figure 2 (a) HPLC chromatogram of mometasone furoate (40 lg mL1) and formoterol fumarate (35 lg mL1). (b) HPLC
chromatogram of mometasone furoate (70 lg mL1), mometasone furoate degradation products and formoterol fumarate (30 lg mL1).
(c) HPLC chromatogram of mometasone furoate (25 lg mL1), formoterol fumarate desformyl derivative and formoterol fumarate
(20 lg mL1).
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3.1. Method development
3.1.1. Mixture 1
Several chromatographic conditions were attempted using C18
and C8 column. Various mobile phase compositions such as
(methanol: H2O), (Acetonitrile: H2O) and (Acetonitrile:
methanol: H2O) in different ratios were tried in an isocratic
mode but optimized separation of all contents was not
obtained. Finally, by using a mixture of 3 mM sodium laurylsulfate and acetonitrile, an improvement has been noticed.
The chromatographic parameters were optimized and the ratio
was kept as acetonitrile:sodium Lauryl sulfate) (60:40 v/v) at a
ﬂow rate of 1 mL min1 and a column temperature of 30 C.
UV detector was operated at 247 nm for determination of
MF and at 214 nm for determination of FF. These conditions
resulted in optimal resolution and peaks sharpness of MF and
FF (Fig. 2a) and their degradation products (Fig. 2b and c)
with a chromatographic analysis time less than 10 min. The
apparent advantages of using surfactant solutions as the
mobile phase in liquid chromatography include the following:
Figure 3 (a) HPLC chromatogram of mometasone furoate (160 lg mL1) and salicylic acid (640 lg mL1). (b) HPLC chromatogram of
mometasone furoate (75 lg mL1), mometasone furoate degradation products and salicylic acid (85 lg mL1).
Table 1 System suitability tests for the proposed LC method
for determination of mometasone furoate, formoterol fumarate
or salicylic acid in mixtures.
Parameter Mixture 1 Mixture 2
MF FF MF SA
Na 5936 1289 5394 1230
Tb 1 1.05 1 0.85
K0 2.72 1.00 2.44 1.00
Resolution 9.06 12.08
%R.S.Dc of 6 injections of
Peak area 0.383 0.641 0.39 0.32
tR
d (min) 0.148 1.02 0.07 0.13
a Number of theoretical plates.
b Tailing factor.
c % Relative standard deviation.
d Retention time.
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highly selective partitioning of many solutes into micelles;
(iii) low cost; and (iv) the ability to change the polarity of
the micellar mobile phase simply by changing the concent-
ration of surfactant in solution. The unique possibilities of
separating structurally similar solutes with a micellar mobile
phase arise because the micelles solubilize and bind a varietyof solute molecules via hydrophobic, electrostatic, and
hydrogen-bonding interactions (Mohammed and Jabeen, 2003).
3.1.2. Mixture 2
During the optimization cycle, several chromatographic condi-
tions were attempted using C18 column. Various mobile phase
compositions such as methanol with water, acetonitrile with
water, methanol with water and glacial acetic acid, in different
proportions, were tried in an isocratic mode. Using the third
composition in different ratio was applicable for separation
of MF and SA but with excessive peak tailing of both. Thus,
introduction of acetonitrile was necessary to optimize shape
and symmetry of peaks. Also, sharpness and symmetry of
SA peak were optimized through switching from C18 to C8
column.
After all these attempts, it was found that a mobile phase
composition of acetonitrile:methanol:water:glacial acetic acid,
(60:10:30:0.1, v/v) at a ﬂow rate of 2 mL min1 and UV detec-
tion at 240 nm using C8 column was the optimum for the sep-
aration of MF and SA (Fig. 3a) along with the degradation
products of MF in minimum runtime (Fig. 3b).
3.2. System suitability tests
System suitability tests are an integral part of liquid chromato-
graphic methods in the course of optimizing the conditions of
Table 2 Assay parameters and method validation obtained by applying HPLC method for the simultaneous determination of
mometasone furoate and formoterol fumarate or salicylic acid in mixturesa.
Parameter Mixture 1 Mixture 2
MF FF MF SA
Retention time (min) 6.51 3.53 4.39 1.4
Wavelength of detection (nm) 247 214 240 240
Range of linearity (lg mL1) 10–800 5–60 5–320 20–1280
Regression equation Area = 59.834 Area = 106.55 Area = 26.006 Area = 15.135
Clg mL
1  150.46 Clg mL1 + 33.166 Clg mL1  0.0746 Clg mL1 + 52.038
Regression coeﬃcient (r2) 0.9998 0.9998 0.9999 0.9995
LOD (lg mL1) 1.571 0.611 0.335 0.705
LOQ (lg mL1) 4.762 1.852 1.016 2.136
Sb 0.301 0.676 0.0899 0.1342
Sa 131.037 24.425 12.56 101.62
Conﬁdence limit of the slope 59.834 ± 141.208 106.55 ± 1.739 26.006 ± 0.2311 15.135 ± 0.3166
Conﬁdence limit of the intercept 150.46 ± 309.249 33.166 ± 62.772 0.0746 ± 32.267 52.038 ± 239.8023
Standard error of the estimation 265.293 33.969 25.256 196.016
Precision the regression 1.1 1.06 0.67 2.02
Inter-day (%R.S.D.) 0.096–0.478 0.142–0.646 0.34–0.52 0.17–0.36
Intra-day (%R.S.D.) 0.119–0.869 0.011–0.503 0.08–0.12 0.05–0.34
Drug in bulk 99.476%± .445 100.624%± 0.587 99.664%± 0.941 100.08%± 0.988
Drug in dosage form 97.81%± 0.702 99.18%± 0.871 100.57%± 0.677 99.59%± 0.345
Standard added 99.015%± 0.728 98.552 ± 0.335 99.95%± 0.683 100.87 ± 0.235
a a = intercept, b = slope, Sa = standard deviation of intercept, Sb = standard deviation of slope.
Figure 4 HPLC chromatogram of Dulera inhaler containing 680 lg mL1 mometasone furoate and 17 lg mL1 formoterol fumarate.
Figure 5 HPLC chromatogram of Elicasal ointment containing 10 lg mL1 of mometasone furoate and 500 lg mL1 of salicylic acid.
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tion and reproducibility were adequate for the analysis per-
formed. The parameters of these tests are column efﬁciency
(number of theoretical plates), tailing of chromatographicpeak, repeatability as %R.S.D of peak area for six injections
and reproducibility of retention as %R.S.D of retention time.
Solutions of 360 lg mL1 and 25 lg mL1 of MF and FF,
respectively, (For mixture 1) and 160 lg mL1 and
(a)                                        (b)    
(c)                                         (d)      
(e)                                              (f)
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D4
D1
D5
D3
D4
D1
D5
D3
D4 D1
D5
D3
D4
D1 D2
D3
D4
D1
D2
D3
D4
Figure 6 HPLC chromatogram of degraded mometasone furoate in (a) 0.1 M NaOH at RT; (b) 0.5 M NaOH at RT; (c) 1 M NaOH at
RT; (d) 0.1 M NaOH at 75 C; (e) 0.5 M NaOH at 75 C; (f) 1 M NaOH at 75 C.
500 R.I. El-Bagary et al.640 lg mL1 of MF and SA, respectively, (For mixture 2) were
used for these tests. The results of system suitability tests for
the proposed method are listed in Table 1.
3.3. Method Validation
3.3.1. Range and linearity
The linearity of the chromatographic methods for the determi-
nation of MF, FF and SA was evaluated by analysing a series
of different concentrations of each drug. In this study, for mix-
ture 1, nine and seven concentrations ranging between 10–
800 lg mL1 and 5–60 lg mL1 for MF and FF, respectively,
were chosen. For mixture 2, seven and nine concentrations
ranging between 5–320 lg mL1 and 20–1280 lg mL1 for
MF and SA, respectively, were chosen. Each concentration
was analysed three times. Good linearity of the calibration
curve was veriﬁed by the high correlation coefﬁcient. The ana-
lytical data of the calibration curve including standard devia-
tions for the slope and intercept (Sb, Sa) are summarized in
Table 2.
3.3.2. Accuracy
Accuracy of the results was calculated by % recovery of labo-
ratory prepared mixtures of 6 different concentrations of MFand FF and 5 different concentrations of MF and SA and also
by standard addition technique for Dulera inhaler and
Elicasal ointment. The results obtained including the mean
of the recovery and standard deviation are displayed in
Table 2.
3.3.3. Precision
The repeatability of the method was assessed by six determina-
tions for each of the three concentrations representing 80%,
100%, 120% for each drug, and for mixture 1, these percent-
ages represent (280, 360 and 420 lg mL1) for MF and (20,
25 and 30 lg mL1) for FF. For mixture 2, these percentages
represent (128, 160 and 192 lg mL1) for MF and (512, 640
and 768 lg mL1) for SA. The repeatability of sample applica-
tion and peak area measurement for active compounds were
expressed in terms of percentage relative standard deviation
(%R.S.D.) and found to be less than 1% in the three concen-
trations. All experiments described in repeatability were
repeated in three consecutive days by the same analyst to eval-
uate day to day ruggedness.
3.3.4. Speciﬁcity
Speciﬁcity is the ability of the analytical method to measure
the analyte response in the presence of interferences. The
Figure 7 HPLC chromatogram of degraded mometasone furoate in (a) 0.1 M HCl at RT; (b) 0.5 M HCl at RT; (c) 1 M HCl at RT; (d)
0.1 M HCl at 75 C; (e) 0.5 M HCl at 75 C; (f) 1 M HCl at 75 C.
Figure 8 HPLC chromatogram of sunlight degraded mometasone furoate.
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were found to be identical to the chromatograms obtained by
the standard solution. Also, no chromatographic interference
from any of the degradation products was found by mixing
alkaline degraded MF solution with FF or SA and by mixingacidic degraded FF solution with MF (Figs. 2 and 3). In
addition, no chromatographic interference from any of the
excipients was found at the retention time of the examined
drug after extraction of the active ingredient (Figs. 4 and
5). Besides, the chromatograms of the pharmaceutical
Figure 9 Mass spectrum of mometasone furoate alkaline degradation products.
502 R.I. El-Bagary et al.formulation samples were checked for the appearance of any
extra peaks. Good resolution and absence of interference
from any of the degradation products resulted under all
stress conditions are shown in (Figs. 6–8). So the proposed
methods could be successfully applied for the routine analysis
of the studied drugs in their dosage forms without any
preliminary separation step. Results for determination of
these drugs by the proposed method in their dosage forms
along with standard addition technique are displayed in
Table 2.3.3.5. Limit of detection and limit of quantitation
Limit of detection (LOD) which represents the concentration
of analyte at S/N ratio of 3 and limit of quantiﬁcation
(LOQ) at which S/N ratio is 10 were determined experimen-
tally for the proposed methods and results are given in Table 2.3.3.6. Robustness
Robustness was performed by deliberately changing the chro-
matographic conditions. For both mixtures, the ﬂow rate of
Figure 10 Structures of mometasone furoate alkaline degradation products.
Table 3 Statistical comparison between the recovery results of
the proposed LC method and the reference methods for the
determination of MF and FF.
Statistical
Term
MF FF
Reference
method
HPLC
method
Reference
method
HPLC
method
Mean 100.02 99.48 99.76 100.62
±S.D. 0.542 0.444 0.939 0.587
±S.E. 0.221 0.181 0.383 0.239
%R.S.D 0.542 0.446 0.941 0.583
n 6 6 6 6
Variance 0.294 0.197 0.882 0.345
t-value 1.890 1.905
(2.228a) (2.228a)
F-value 1.492 2.557
(5.050a) (5.050a)
a Figures in parentheses are the theoretical t and F values at
(p= 0.05), while n is number of determinations.
Table 4 Statistical comparison between the recovery results of
the proposed LC methods and the reference methods for the
determination of MF and SA.
Statistical
term
MF SA
Reference
method
HPLC
method
Reference
method
HPLC
method
Mean 100.02 99.65 99.77 100.08
±S.D. 0.542 0.950 0.845 0.988
±S.E. 0.221 0.425 0.345 0.442
%R.S.D 0.542 0.953 0.847 0.987
n 6 5 6 5
Variance 0.294 0.903 0.714 0.976
t-value 0.772 0.553
(2.260*) (2.260*)
F-value 3.071 1.367
(5.190*) (5.190*)
* Figures in parentheses are the theoretical t and F values at
(p= 0.05), while n is number of determinations.
Forced degradation of mometasone furoate and development of two RP-HPLC methods 503the mobile phases was changed by ±0.2 units. The organic
strengths were varied by ±2%. These variations did not have
signiﬁcant effect on chromatographic resolution by the pro-
posed LC methods.
4. Degradation behaviour of mometasone furoate
4.1. Acid- and base-induced degradation
The chromatograms of the alkaline degraded samples for
mometasone furoate using different molarities of NaOH oncold, showed complete disappearance of the intact drug and
appearance of additional four peaks (D1, D2, D3 & D4) at
retention times of 2.5, 3.7, 4 and 5.9 min. (Fig. 6a–c), while
using different molarities of NaOH on hot showed complete
disappearance of degradation product which appear at
3.7 min (D2) and introduction of a new one at 2.9 min (D5)
(Fig. 6d–f).
Acidic degradation studies showed no additional peaks,
which indicates that mometasone furoate is acid stable (Fig. 7).
Veriﬁcation of the products was carried out using LC–MS,
and all mass spectra are illustrated in Fig. 9. The major peak
504 R.I. El-Bagary et al.[D4 (Mwt: 466.453), Retention time 5.9 min] has a molecular
ion peak 466.92 (M+), which may correspond to structure
(a) in Fig. 10. The mechanism of the reaction has been pro-
posed by Foe et al. (1998). It involves a stereospeciﬁc nucle-
ophilic attack of the 11b-hydroxyl on C-9 on departure of
the 9-halogen, leading to the formation of 9b, 11b-epoxide
derivative in addition to a rearrangement of the furoate moiety
and dehydration on the C-17 side-chains ofMF. The two other
peaks [D1 (Mwt: 390.453) and D3 (Mwt: 484.453), Retention
time 2.5 and 4.0 min] have the molecular ion peaks of 388.3
(M-2) and 484.12 (M+) which may correspond to structures
(b) & (c), respectively. Epoxide formation was accompanied
by ester hydrolysis resulted in the formation of structure (b)
while structure (c) was found as a result from epoxide forma-
tion without the rearrangement of the furoate moiety and the
dehydration. In addition, a fourth degradation product D2
(Mwt: 426.906), (Retention time 3.7 min with a molecular
ion peak 426.82 (M+) which may correspond to structures
(d) in Fig. 10 was found as a result from furoate ester hydrol-
ysis. Structure (a) was the major degradation product.
4.2. Hydrogen peroxide-induced degradation
The sample degraded with 3% and 15% v/v hydrogen perox-
ide either on cold or after heating at 80 C for 1 h showed
no additional peaks. This was conﬁrmed by good percentage
recovery of the intact drug.
4.3. Thermal and photolytic degradation
The samples degraded under dry heat conditions showed no
additional peaks. On the other hand, the photodegraded sam-
ple showed an additional peak D2 at retention time 3.7 min
when drug solution was exposed to sunlight for 72 h (Fig. 8).
From the aforementioned data, the drug was found to be
susceptible to base hydrolysis and photodegradation but resis-
tant to acid hydrolysis, oxidation and dry heat degradation.
5. Statistical studies
Statistical comparison between the results of the proposed
methods and those obtained by the reference methods for
MF according to U.S.P 37 (USP, 2014) and for FF and SA
according to BP (BP, 2014), respectively showed no signiﬁcant
difference. Results were compared using the Student’s t-test
and F-ratio. It can be concluded that the proposed analytical
methods are sufﬁciently accurate and precise and results are
given in Tables 3 and 4.
6. Conclusion
Two validated LC methods were developed for the simultane-
ous determination of (mometasone furoate, formoterol fuma-
rate) and (mometasone furoate, salicylic acid) mixtures along
with mometasone furoate alkaline degradation products for
both mixtures and with Formoterol fumarate acidic degrada-
tion product for mixture 1. Moreover, a full study of the degra-
dation behaviour of mometasone furoate under acid, alkali,
oxidation, thermal and photolysis conditions was carried
out. The drug was found to be degraded in alkaline andphotolytic conditions and found to be stable to acidic, oxida-
tion and dry heat conditions. The proposed methods could
be successfully applied for the routine analysis of the studied
drugs either in their pure bulk powders or in their dosage
forms without any preliminary separation step.
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